Lysosomal storage disorders: A brief overview
=============================================

Inborn errors of metabolism are a common cause of inherited disease ([@bib15]), of which lysosomal storage diseases (LSDs) are a significant subgroup ([@bib88]; [@bib38]; [@bib5]). The combined incidence of LSDs is estimated to be approximately 1:5,000 live births ([@bib38]), but the true figure is likely greater when undiagnosed or misdiagnosed cases are accounted for. Common to all LSDs is the initial accumulation of specific macromolecules or monomeric compounds inside organelles of the endosomal--autophagic--lysosomal system. Initial biochemical characterization of stored macromolecules in these disorders led to the implication of defective lysosomal enzymes as a common cause of pathogenesis ([@bib48]; [@bib130]). Although most LSDs result from acidic hydrolase deficiencies ([@bib130]), a considerable number of these conditions result from defects in lysosomal membrane proteins or non-enzymatic soluble lysosomal proteins ([@bib96]). Therefore, LSDs offer a window into the normal functions of both enzymatic and non-enzymatic lysosomal proteins.

Clinical phenotypes of LSDs
===========================

The age of clinical onset and spectrum of symptoms exhibited amongst different LSDs vary, depending on the degree of protein function affected by specific mutations, the biochemistry of the stored material, and the cell types where storage occurs. Apart from lysosomal diseases involving substrate storage in bone and cartilage (e.g., the mucopolysaccharidoses; [Table 1](#tbl1){ref-type="table"}) most babies born with these conditions appear normal at birth. The classical clinical presentation of an LSD is a neurodegenerative disease of infancy/childhood ([@bib135]), but adult-onset variants also occur ([@bib109]; [@bib78]; [@bib106]). A health surveillance program tasked with diagnosing all neurodegenerative disease cases in UK children has so far revealed that lysosomal disorders are amongst the most commonly confirmed diagnoses of neurodegeneration (45% of cases) and will provide a robust frequency of infantile/juvenile onset cases as the study gathers more data over the coming years ([@bib123]). Key molecular and clinical features of the storage diseases mentioned in this review are summarized in [Table 1](#tbl1){ref-type="table"}. In addition, detailed medical descriptions on the various disorders are available on the Online Metabolic and Molecular Bases of Inherited Disease (OMMBID) website ([@bib121]).

###### 

The causes of lysosomal storage diseases, the organelles affected, and major sites of pathology

  Mechanism of lysosomal storage                        Disease examples                                                  Lysosomal protein defect (gene symbol)                                                                                                                                                                       Substrate(s) stored                                                                                                     Major peripheral organ systems affected   CNS pathology
  ----------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------- -------------------------------------
  Lysosomal enzyme deficiencies                         Aspartylglucosaminuria                                            Aspartylglucosaminidase (glycosylasparaginase, AGA)                                                                                                                                                          aspartylglucosamine (*N*-acetylglucosaminyl-asparagine)                                                                 Skeleton, connective tissue               \+
                                                        Fabry                                                             α-Galactosidase (GLA)                                                                                                                                                                                        (Lyso-)Globotriaosylceramide                                                                                            Kidney, heart                             −
                                                        Gaucher types 1, 2, and 3                                         β-Glucocerebrosidase (GBA)                                                                                                                                                                                   Glucosylceramide, glucosylsphingosine                                                                                   Spleen/liver, bone marrow                 \+[a](#tblfn1){ref-type="table-fn"}
                                                        GM1-gangliosidosis                                                β-Galactosidase (GLB1)                                                                                                                                                                                       GM1-ganglioside, oligosaccharides                                                                                       Skeleton, heart                           \+
                                                        Krabbe (globoid cell leukodystrophy)                              Galactocerebrosidase (GALC)                                                                                                                                                                                  Galactosylceramide                                                                                                      Heart                                     \+
                                                        Metachromatic leukodystrophy                                      Arylsulfatase A (ARSA)                                                                                                                                                                                       Sulfogalactosylceramide                                                                                                                                           \+
                                                        Mucopolysaccharidoses                                             Enzymes involve in mucopolysaccharide catabolism                                                                                                                                                             Mucopolysaccharides                                                                                                     Cartilage, bone, heart, lungs             \+[b](#tblfn2){ref-type="table-fn"}
                                                        Multiple sulfatase deficiency                                     SUMF1 (Formylglycine-generating enzyme needed to activate sulfatases)                                                                                                                                        Multiple, including sulfated glycosaminoglycans                                                                         Spleen/liver, bone, skin                  \+
                                                        Pompe                                                             α-Glucosidase (GAA)                                                                                                                                                                                          Glycogen                                                                                                                Skeletal muscle                           −
                                                        Sandhoff                                                          β-hexosaminidase A and B (HEXB)                                                                                                                                                                              GM2-ganglioside                                                                                                                                                   \+
  Trafficking defect of lysososomal enzymes             Mucolipidosis type II (I-cell disease)                            *N*-acetyl glucosamine phosphoryl transferase α/β (GNPTAB)                                                                                                                                                   Carbohydrates, lipids, proteins                                                                                         Skeleton, heart                           \+
                                                        Mucolipidosis type IIIA (pseudo-Hurler polydystrophy)             *N*-acetyl glucosamine phosphoryl transferase α/β (GNPTAB)                                                                                                                                                   Carbohydrates, lipids, proteins                                                                                         Skeleton, heart                           +/−
  Defects in soluble non-enzymatic lysosomal proteins   Niemann-Pick disease type C2                                      NPC2 (soluble cholesterol binding protein)                                                                                                                                                                   Cholesterol and sphingolipids                                                                                           Liver                                     \+
  Defects in lysosomal membrane proteins                Cystinosis                                                        Cystinosin (cysteine transporter, CTNS)                                                                                                                                                                      Cystine                                                                                                                 Kidney, eye                               −
                                                        Danon disease                                                     Lysosomal-associated membrane protein 2, splicing variant A (LAMP2)                                                                                                                                          Glycogen and other autophagic components                                                                                Cardiac and skeletal muscle               \+
                                                        Free sialic acid storage disorder                                 Sialin (sialic acid transporter, SLC17A5)                                                                                                                                                                    Free sialic acid                                                                                                        Liver/spleen, skeleton                    \+
                                                        Mucolipidosis IV                                                  Mucolipin-I (MCOLN1)                                                                                                                                                                                         Mucopolysaccharides and lipids                                                                                          Eye                                       \+
                                                        Niemann-Pick disease type C1                                      NPC1 (membrane protein involved in lipid transport)                                                                                                                                                          Cholesterol and sphingolipids                                                                                           Liver                                     \+
  Enigmatic lysosomal disorders                         Neuronal ceroid lipofuscinoses (NCLs, including Batten disease)   Disparate group of diseases with genetic defects in apparently unrelated genes, not all of which are associated with the lysosomal system. Not known if these genes cooperate in common cellular pathways.   Autofluorescent lipofuscin is a common feature, with convergent clinical signs, e.g., visual system defects/blindness                                             \+

Listed are the diseases discussed in the main text. Mucopolysaccharidoses and neuronal ceroid lipofuscinoses refer to collections of related disorders.

Types 2 and 3.

Most mucopolysaccharidosis disorders.

Relatively few lysosomal diseases lack pathology in the central nervous system (CNS; [@bib136]). In the majority of LSDs, CNS involvement is common and neurodegeneration can occur in multiple brain regions (e.g., thalamus, cortex, hippocampus, and cerebellum). Neuropathology in LSDs involves unique temporal and spatial changes, which often entails early region-specific neurodegeneration and inflammation, before global brain regions are affected. The main reasons for this are threefold: (1) specific storage metabolites exert differential effects on neuronal subtypes, (2) varying proportions of macromolecules are synthesized in different neuronal populations, and (3) there is differential neuronal vulnerability to storage (e.g., Purkinje neurons degenerate in many of these diseases leading to cerebellar ataxia). Activation of the innate immune system is also prevalent in the brain of LSDs, which directly contributes to CNS pathology ([@bib124]). Astrogliosis (activation of astrocytes) is another common feature of LSDs, which damages neurons through an inflammatory process known as glial scarring ([@bib51]; [@bib124]). The additive detrimental effects that astrogliosis has on neuron function is recapitulated in animal models of lysosomal diseases ([@bib35]; [@bib90]).

A notable non-neuronopathic LSD is Type 1 Gaucher disease (β-glucocerebrosidase deficiency), which is a relatively common LSD, particularly within the Ashkenazi Jewish community. The major cell type affected by glucosylceramide storage in this disease is the macrophage ("Gaucher cells"), whose dysfunction affects the production and turnover of cells belonging to the hematopoietic system. Gaucher cells infiltrate into various organs and affect the immune system, bone strength, spleen, and liver function.

A key question currently challenging this field is how endosomal--lysosomal storage leads to pathogenesis and how expanding this knowledge will improve treatment for patients ([@bib7]; [@bib23]). This review aims to delineate regulatory systems and organelles that become disrupted in these disorders, highlighting the complexity of cellular storage, its consequences on pathogenesis, and implications for therapy.

Endosomal--autophagic--lysosomal function and dysfunction in storage diseases
=============================================================================

Lysosomes play a central role in processing the clearance of cellular substrates from multiple routes within the endosomal--autophagic--lysosomal system ([Fig. 1](#fig1){ref-type="fig"}). Lysosomes are acidic organelles that contain enzymes required for the degradation of macromolecules, and efflux permeases that facilitate the inside-out translocation of small molecules generated through macromolecule catabolism. In comparison to endosomes and autophagosomes, lysosomes are smaller in size, are highly enriched in particular transmembrane proteins and hydrolytic enzymes (including proteases, glycosidases, nucleases, phosphatases, and lipases), have a higher buoyant density, an electron-dense appearance by transmission electron microscopy, and a high proton and Ca^2+^ content ([@bib70]; [@bib96]; [@bib73]). Lysosomes differ from endosomes in their degree of acidification and more abundant levels of lysosomal membrane proteins (LMPs) such as LAMP1 and LAMP2. Most nascent lysosomal enzymes bind to mannose-6-phosphate receptors (M6PRs) in the trans-Golgi network (TGN), which traffic the enzymes to early and late endosomes ([@bib42]). Lysosomes in turn receive these enzymes when endosomal--lysosomal fusion occurs. Notably, dense lysosomes do not contain M6PRs. Acidotropic reagents such as Lysotracker are useful for labeling lysosomes; however, the mildly acidic interiors of late endosomes and autophagosomes also allows Lysotracker to label these organelles to varying degrees ([@bib6]).

![**Lysosomes as catabolic centers of the cell.** Lysosomes utilize four distinct pathways for the degradation of cellular material. (A) Macroautophagy begins with the formation of isolation membranes that sequester regions of the cytosol that include denatured proteins, lipids, carbohydrates, and old/damaged organelles into encapsulated vesicles known as autophagosomes. The dynamic kinetics of autophagosome production and clearance by lysosomes is known as autophagic flux. (B) Endosomal degradation by lysosomes predominantly targets late endosomes/multivesicular bodies. Fusion between late endosomes and lysosomes can occur by (i) full fusion/degradation or (ii) kiss-and-run content mixing, where transient endosomal docking occurs. (C) Microautophagy involves the pinocytosis of cytosolic regions surrounding lysosomes. (D) Chaperone-mediated autophagy (CMA) selectively targets proteins with a KFERQ motif for delivery to lysosomes using Hsc-70 as its chaperone and LAMP-2A as its receptor.](JCB_201208152R_Fig1){#fig1}

The biogenesis and functioning of endosomal and autophagosomal pathways is controlled by transcription factor EB (TFEB), which regulates the expression of 471 genes that constitute the CLEAR (coordinated lysosomal expression and regulation) gene network ([@bib99]; [@bib82]). Recent work indicates that non-active TFEB is highly phosphorylated and associates with late endosomes/lysosomes ([@bib95]). Autophagy-inducing conditions (e.g., deprivation of glucose or amino acids) result in reduced and altered TFEB phosphorylation, leading to its translocation into the nucleus ([@bib84]) and transcriptional expression of CLEAR genes ([@bib82]).

Degradation of endosomal and autophagosomal material takes place upon exchange of content (via transient "kiss-and-run" contacts) or fusion with lysosomes, forming endolysosomes ([@bib118]; [@bib12], [@bib13]; [@bib75]) and autolysosomes ([@bib49]; [@bib33]; [@bib80]), respectively ([Fig. 1, A and B](#fig1){ref-type="fig"}). Lysosomes can be regarded as storage compartments for acidic hydrolases that enter cycles of fusion and fission with late endosomes and autophagosomes, while the digestion of endocytosed and autophagic substrates takes place primarily in endolysosomes and autolysosomes ([@bib118]; [@bib70]). Under physiological conditions, endolysosomes and autolysosomes are transient organelles.

Cells deficient in lysosomal hydrolytic enzymes, lysosomal membrane proteins, or non-enzymatic soluble lysosomal proteins accumulate excessive levels of undegraded macromolecules (enzyme deficiency) or monomeric catabolic products (efflux permease deficiency) and contain numerous endo/autolysosomes ([Fig. 2](#fig2){ref-type="fig"}). When very high levels of macromolecules/monomers accumulate in endo/autolysosomes, they inhibit catabolic enzymes and permeases that are not genetically deficient, which results in secondary substrate accumulation ([@bib127]; [@bib64]; [@bib91]). For example, lysosomal proteolytic capacity is reduced in fibroblasts from various LSDs, such as mucopolysaccharidoses I and VI, and GM1-gangliosidosis, which are themselves not caused by protease deficiency ([@bib60]). The accumulation of primary and secondary substrates sets off a cascade of events that impacts not only the endosomal--autophagic--lysosomal system, but also other organelles, including mitochondria, the ER, Golgi, peroxisomes ([Fig. 3](#fig3){ref-type="fig"}), and overall cell function ([Fig. 4](#fig4){ref-type="fig"}).

![**Subtypes of storage organelles accumulate in LSDs.** In different LSDs, cells display a unique spectrum of dysfunctional organelles depending on the specific lysosomal enzyme or non-enzymatic protein affected. (A) In primary LSDs, deficiencies in degradative enzymes prevent the clearance of autophagic and endocytic substrates, resulting in the accumulation of (i) autolysosomes (LC3-II (+), LAMP-1 (+)), (ii) endolysosomes (CI-MPR (+), LAMP-1 (+)), and (iii), in the case of certain lipase deficiencies, lipid-rich multilamellar bodies (CI-MPR (+), LAMP-1 (+)). (B) In a secondary storage disease such as Niemann-Pick type C1, lysosomal enzyme function remains intact, but impaired heterotypic fusion of autophagic and endocytic organelles with lysosomes results in the accumulation of (iv) autophagosomes (LC3-II (+), LAMP-1 (−)), (v) late endosomes (CI-MPR (+), active cathepsin D (−)), and (vi) endosome-derived multilamellar bodies (lipid-rich, CI-MPR (+), active cathepsin D (−)). Note: many primary storage diseases also accumulate organelles seen in secondary storage diseases (see text).](JCB_201208152_Fig2){#fig2}

![**Summary of organelles affected in LSDs.** Also shown are selective examples of LSDs. See [Table 1](#tbl1){ref-type="table"} and main text for details.](JCB_201208152_Fig3){#fig3}

![**Hypothetical cascade of events in LSD pathology.** How gene mutations in lysosomal enzymes and non-enzymatic lysosomal proteins could lead to LSDs. Endo/autolysosomal events are confined to the darker shaded background, whereas processes taking place in the cytoplasm that affect autophagosomes, the ER, Golgi, peroxisomes, and mitochondria are on the lighter background. Processes depicted have been observed in a number of LSDs but do not necessarily apply to all LSDs.](JCB_201208152_Fig4){#fig4}

Autophagic pathways.
--------------------

The autophagic ("self-eating") pathway constitutively targets intracellular cytosolic components for lysosomal degradation, and is essential for maintaining cellular energy and metabolic homeostasis ([@bib62]; [@bib108]). To date, three distinct forms of autophagy have been characterized: macroautophagy, microautophagy, and chaperone-mediated autophagy ([Fig. 1, A, C, and D](#fig1){ref-type="fig"}). All three autophagic processes culminate in lysosomal degradation; however, routes taken by substrates to the lysosome differ between each form. Macroautophagy involves the bulk sequestration of cytosolic regions into double- or multi-membrane bound autophagosomes, which are trafficked to lysosomes for content digestion ([Fig. 1 A](#fig1){ref-type="fig"}). A diverse range of cellular material is degraded via macroautophagy, including lipids, carbohydrates and polyubiquitinated proteins, RNA, mitochondria, and fragments of the ER ([@bib29]). The most characterized protein associated with autophagosomes is the lipidated (phosphatidylethanolamine) form of microtubule-associated protein light chain 3 (MAP-LC3), known as LC3-II, which is generated early in the autophagic process but degraded in the final phase of autophagic digestion.

Autophagic flux (the rate at which autophagic vacuoles are processed by lysosomes) is reduced in most LSDs ([@bib4]; [@bib5]; [@bib93]). This is evident from the combined elevation of autophagic substrates and autophagosome-associated LC3-II. LSD cells often display increased numbers of LC3(+) organelles, of which only a subgroup carry lysosomal markers, suggesting that both autophagosomes and autolysosomes persist in these conditions. For example, in mouse models of Batten disease (a neuronal ceroid lipofuscinosis \[NCL\] disorder; [Table 1](#tbl1){ref-type="table"}), most LC3-positive compartments are not positive for LAMP1 ([@bib59]), and in multiple sulfatase deficiency and juvenile neuronal ceroid lipofuscinosis, LC3 and LAMP1 are predominantly localized in separate organelles, which is even more pronounced after starvation ([@bib16]; [@bib105]). Endosome--lysosome and autophagosome--lysosome fusion is also impaired in mucolipidosis type IIIA and multiple sulfatase-deficient mouse embryonic fibroblasts ([@bib37]).

Microautophagy does not involve de novo synthesis of nascent vacuoles, but rather occurs via the direct pinocytosis of cytosolic material by lysosomes ([Fig. 1 C](#fig1){ref-type="fig"}). The membrane dynamics regulating microautophagy are similar to those involved in the formation of intra-luminal vesicles (ILVs) found in multivesicular bodies/late endosomes ([@bib97]). Currently, little is known about the repercussions of lysosomal storage on microautophagy, but this process appears to be impaired in primary myoblasts from patients with the muscle-wasting condition Pompe disease ([@bib113]).

Chaperone-mediated autophagy (CMA) is a selective form of autophagic proteolysis that targets proteins containing a KFERQ motif for degradation ([@bib26]; [@bib24]). The eponymous chaperone that recognizes and binds to proteins destined for CMA is the heat shock cognate protein of 70 kD (Hsc70). Substrate-bound Hsc70 docks on lysosomes via contact with lysosomal-associated membrane protein 2A (LAMP-2A), allowing entry of proteins into lysosomes ([Fig. 1 D](#fig1){ref-type="fig"}). Mutations in LAMP-2A cause Danon disease, and specifically affect CMA ([@bib30]; [@bib36]). CMA is also known to be impaired in mucolipidosis IV, where mutations in transient receptor potential mucolipin-1 (MCOLN1) lead to reduced amounts of LAMP-2A and substrate uptake into lysosomes ([@bib122]).

Lysosome reformation.
---------------------

Both endolysosomes and autolysosomes extend tubular structures where lysosomal hydrolases and LMPs concentrate ([@bib118]; [@bib12], [@bib13]; [@bib92]; [@bib138]). At the ends of these tubules, \[LC3(−), LAMP1(+)\] vesicles bud off and acidify, maturing into dense lysosomes, a fission process referred to as lysosome reformation. This event completes each cycle of endocytic and autophagic degradation, yielding dense lysosomes that are available to fuse with newly generated endosomes and autophagosomes.

Efficient processing of endo/autolysosomal substrates is essential for lysosome reformation. This is well illustrated in a study that monitored exogenous sucrose metabolism in rat kidney fibroblasts ([@bib12]). Sucrose is a disaccharide composed of the monosaccharides glucose and fructose, and is itself indigestible by cells. In this study, sucrose-filled endosomes fused with lysosomes and formed large endolysosomes, which accumulated in the cytosol. A depletion of dense-core lysosomes was seen under these conditions; however, dissolution of the accumulated sucrose by uptake of exogenous invertase resulted in the reappearance of dense-core lysosomes. This study and another more recent one from [@bib138] indicate that lysosome biogenesis does not occur de novo, but is rather born out of a reformation/budding from endolysosomes. Lysosome reformation appears to be defective in sialic acid storage disease as skin fibroblasts from diseased individuals lack dense lysosomes, while lysosomal enzymes persist in intermediate or light organelles ([@bib102]).

Interestingly, impairment of lysosome reformation appears to be the primary cellular defect in Niemann-Pick type C2 (NPC2)-deficient cells, indicating that the NPC2 protein has a crucial role in this process ([@bib44]). Considering that NPC1 and NPC2 deficiencies have the same pathological consequences (Niemann-Pick type C disease; [Table 1](#tbl1){ref-type="table"}), this suggests that lysosome reformation is as essential as endosome/autophagosome--lysosome fusion, which is impaired in NPC1-deficient cells.

Recent reports have provided a mechanistic link between the failure of endo/autolysosomal clearance and the deficit of lysosome reformation. Central to this pathway is mTOR, a serine/threonine kinase that has an overarching role in coordinating cellular metabolism with nutritional status ([@bib65]). During the course of the autophagic process, mTOR goes through a cycle of phosphorylation-dependent inactivation and reactivation, with the latter being required for autophagic lysosome reformation ([@bib138]). In turn, mTOR reactivation depends on the completion of autolysosomal substrate digestion, and sufficient levels of luminal amino acids ([@bib140]). Limited information is currently available on the extent of lysosome reformation and mTOR reactivation in LSDs. However, inadequate autolysosomal degradation may preclude mTOR reactivation and, hence, also impede lysosome reformation, leaving affected cells deprived of dense lysosomes. Consequently, in addition to stalled autolysosomes, autophagosomes may persist due to a deficiency of dense lysosomes, explaining the low level of colocalization of autophagosomal and lysosomal markers. mTOR activity is reduced in the brain of a mouse model of juvenile neuronal ceroid lipofuscinosis ([@bib16]), in fibroblasts from mucopolysaccharidosis type I S, Fabry disease and aspartylglucosaminuria subjected to starvation-induced autophagy ([@bib138]), in NPC1- and NPC2-knockdown human umbilical vein endothelial cells ([@bib137]), and in MCOLN1-deficient *Drosophila* pupae ([@bib132]), but not in brain samples from Sandhoff, GM1-gangliosidosis, and NPC1 mice ([@bib8]). Considering the myriad of cellular signaling pathways that mTOR is involved in ([@bib65]), it may be necessary to differentiate mTOR activity in affected cell populations of different brain regions. In addition, electron microscopy remains a powerful tool for the ultrastructural classification of autophagosomes and autolysosomes in LSD cells, and could also be used to monitor the extent of lysosome reformation.

Mitochondrial dysfunction and cytoplasmic protein aggregation.
--------------------------------------------------------------

In LSDs, a reduction of autophagic flux has a major impact on mitochondrial function and on cytoplasmic proteostasis. Constitutive macroautophagy maintains mitochondrial quality by selectively degrading dysfunctional mitochondria via a process known as mitophagy ([@bib54]). Mitochondrial proteins are consistently found in the proteomes of highly purified autolysosomes, especially subunits of the mitochondrial ATPase ([@bib103]). Reduced autophagic flux in LSDs leads to the persistence of dysfunctional mitochondria, which is highly pronounced in Batten's disease neurons ([@bib32]). Several LSDs (mucolipidosis types IV, IIIA \[pseudo-Hurler polydystrophy\], and II \[I-cell disease\], late infantile neuronal ceroid lipifuscinosis \[CLN2\], mucopolysaccharidosis VI, and GM1 gangliosidosis) display mitochondrial abnormalities, including replacement of the extended filamentous mitochondrial network with high numbers of relatively short mitochondria, and loss of mitochondrial calcium-buffering capacity and membrane potential ([@bib50]; [@bib105]; [@bib112]; [@bib116]). Studies into aging and autophagosome formation have shown that mitochondria are involved in signaling pathways regulating apoptosis and innate immunity, and that reduced autophagic flux and subsequent accumulation of dysfunctional, reactive oxygen species--generating mitochondria renders cells more sensitive to apoptotic and inflammatory stimuli ([@bib114]; [@bib45]; [@bib76]; [@bib139]). Therefore, the aberrant functioning of mitochondria may be responsible for apoptosis and inflammation in the CNS of multiple LSDs.

In addition, a lack of autophagy completion in LSDs leads to the persistence of ubiquitinated and aggregate-prone polypeptides in the cytoplasm, including p62/SQSTM1, α-synuclein, and Huntingtin protein ([@bib94]; [@bib111]; [@bib105]; [@bib116]). Alpha-synuclein itself contributes to neurodegeneration by reducing the efficiency of autophagosome formation ([@bib131]), and is also a main component of Lewy bodies that are notably elevated in Parkinson's disease and other forms of dementia. Diminished quality control of cytosolic proteins may thus also contribute to LSD pathology.

Impairment of autophagy and escalation of cytoplasmic protein aggregation are shared between neurodegenerative LSDs and more common neurodegenerative disorders, such as Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis (ALS; [@bib41]; [@bib133]). Mutations in presenilin-1, which cause a familial form of Alzheimer's disease, is known to impair lysosomal clearance of autophagosomes ([@bib31]; [@bib129]; [@bib67]). Different mechanisms have been proposed to explain how the partial loss of presenilin function impairs autophagic flux. Reports from [@bib67] indicate that presenilin 1 is need for the glycosylation and subsequent delivery of V0a1 protein to lysosomes, where it forms a subunit of lysosomal v-ATPase. This in turn is thought to impair lysosomal proteolysis by raising their pH above an optimal acidity of pH4--5. Alternatively, another recent report has indicated that mutations in presenilin 1 lead to a loss of lysosomal calcium regulation, which in turn affects fusion and clearance of autophagosomes ([@bib21]). However, considering both groups confirmed that presenilin 1 mutations affect autophagic flux, Alzheimer's disease is beginning to emerge as a neurodegenerative disorder that may share similarities in terms of underlying pathogenic mechanisms with lysosomal storage disorders.

Efflux of molecules from endo/autolysosomes.
--------------------------------------------

Some storage molecules in LSDs (glycoconjugates, amino acids, or insoluble lipids) escape from cells and can be detected in blood and/or urine, which can be utilized for diagnostic purposes ([@bib72]). While glycoconjugates derived from storage cells in multiple tissues could escape as solutes in blood and urine, lipids extracted from urine are believed to be membrane associated and predominantly exosomal ([@bib85]).

At the cellular level, a big question that remains to be resolved concerns the way in which storage molecules escape the lysosomal system and affect the function of other organelles and cellular systems ([@bib28]). Theoretically, lipids can undergo redistribution within cells via membrane trafficking, fusion, or via altered trafficking pathways characteristic of these diseases ([@bib18]). Endolysosomal macromolecules may also be disseminated via membrane contact sites between endolysosomes and the ER ([@bib27]; [@bib120]), and by extracellular secretion of endolysosomal content, including exosome release. For example, primary kidney cells from arylsulfatase A--deficient mice secrete the accumulating lipid (sulfogalactosylceramide) into the culture medium ([@bib58]), and NPC1-deficient cells release higher amounts of cholesterol-rich exosomes ([@bib19]; [@bib110]). Accordingly, the possibility needs to be considered that exosomes containing storage molecules are taken up by recipient cells, and that these macromolecules and lipids affect recipient cell function by distributing to the plasma membrane and other organelles outside the endolysosomal system ([@bib107]).

Due to the extraordinarily high levels of lipids in the endo/autolysosomal system, even a minor redistribution to other cellular membranes could have functional implications. Over the past few years, multiple examples have emerged suggesting that this not only occurs but can actively contribute to the pathogenic cascade ([@bib124]). A key challenge is to demonstrate experimentally that particular storage macromolecules are indeed ectopically present in the membrane of other organelles. This is technically challenging due to the limitations of conventional cell fractionation techniques. Currently, the presence of storage components in non-lysosomal sites is either inferred indirectly or evidence has been provided by immunostaining methods. To date, the best examples come from studying the effects of lipid storage in the ER ([@bib98]; [@bib39]).

Lysosomal calcium homeostasis.
------------------------------

Endosomes and lysosomes are regulated calcium stores ([@bib73]) that release calcium in response to the second messenger nicotinic acid adenine dinucleotide phosphate (NAADP; [@bib20]). NPC1 disease is unusual in having a profound block in late endosome--lysosome fusion ([@bib53]; [@bib44]), a process known to be calcium dependent ([@bib69]). In NPC1 patient cells and cultured cells deficient in NPC1 protein, calcium levels within acidic organelles are approximately 30% of wild-type cells ([@bib69]; [@bib66]). NPC1 cells do respond to NAADP, but, due to the reduced luminal calcium levels, release less calcium, thus leading to the fusion deficiency associated with this disorder ([@bib69]). Therefore, NPC1 disease demonstrates that acidic calcium stores play a central role in the regulation of fusion and trafficking within the endocytic system itself ([@bib73]).

Endoplasmic reticulum defects.
------------------------------

In addition to the endoplasmic reticulum (ER) being the major site of the secretory pathway responsible for protein folding/quality control and N-glycosylation, it is also a regulated calcium store. The lipid and protein content of the ER is tightly regulated to maintain its essential quality-control functions. Surprisingly, very few examples of ER stress (e.g., unfolded protein response) have been reported among LSDs, with GM1 gangliosidosis being the only sphingolipid storage disorder in which this has been demonstrated to date ([@bib115]; [@bib98]; [@bib124]). Instead, the major impact in lipid storage disorders is on ER calcium regulation ([@bib40]; [@bib39]). ER calcium homeostasis is perturbed in the sphingolipid storage disorders, Gaucher disease, GM1 and GM2 gangliosidoses, and Niemann-Pick type A ([@bib43]), leading to elevated cytosolic calcium. In these diseases, the characteristic lipids being stored, glucosylceramide, GM1 and GM2 ganglioside, and sphingomyelin, respectively, may hypothetically escape from endolysosomes and affect ER calcium channel function. Interestingly, the mechanisms leading to defective ER calcium homeostasis are specific to each disorder and have recently been reviewed ([@bib124]). In turn, aberrant ER calcium regulation may impact mitochondria through ER--mitochondria contact sites, resulting in mitochondrial calcium excess and an induction of mitochondria-mediated apoptosis, as seen in GM1 gangliosidosis ([@bib98]).

The Golgi.
----------

Dysfunction of the Golgi is a common feature of many lipid storage disorders, and has traditionally been thought to arise from alterations in sphingolipid trafficking from the Golgi to the lysosome ([@bib81]). However, recently Golgi involvement has been demonstrated in mucopolysaccharidosis IIIB (Sanfillipo B syndrome; [@bib125]). Surprisingly, this study did not find any evidence that the endocytic and autophagic pathways were affected in Sanfillipo B syndrome; instead, they noticed that large storage bodies were enriched in the Golgi matrix protein, GM130, which is required for vesicle tethering in pre- and cis-Golgi compartments. Furthermore, the morphology of the Golgi apparatus was altered in cells with distended cisternae connected to LAMP1-postive storage bodies. This study therefore suggests that Golgi biogenesis may be affected in this disease and further studies will shed light on the molecular mechanisms that underpin Golgi involvement in this neurodegenerative disorder.

Peroxisomes.
------------

There are reports of peroxisomal dysfunction occurring in some lipid lysosomal storage diseases, including Krabbe (globoid cell leukodystrophy; [@bib47]) and NPC1 disease ([@bib100]). In Krabbe disease, the major storage lipid galactosylceramide is converted into its lysosomal metabolite, galactosylsphingosine, which down-regulates the peroxisome proliferator--activated receptor-α (PPAR-α). Loss of PPAR-α and subsequent cell death can be prevented using an inhibitor of secretory phospholipase A2, suggesting a novel therapeutic approach for Krabbe disease ([@bib47]). In the NPC1 disease mouse model, peroxisomes appear normal at the ultrastructural level but have decreased peroxisomal β oxidation of fatty acids and catalase activity, which is an early event in disease pathogenesis ([@bib100]). In peroxisomal biogenesis disorders such as Zellweger syndrome and infantile Refsum disease, a-series gangliosides (e.g., GM1, GM2) and their precursor GM3 ganglioside are stored. As these gangliosides are common secondary storage metabolites in many LSDs, this raises the possibility that peroxisomal dysfunction underpins secondary ganglioside storage in LSDs and merits systematic study to test this hypothesis. How peroxisomal function affects ganglioside metabolism remains unknown but may be part of a broader lipid regulatory network in mammalian cells.

Cellular metabolic stress.
--------------------------

Considering that both endocytic and autophagic pathways are essential for maintaining cellular metabolic homeostasis, the diminished efflux of monomeric products from endo/autolysosomes is likely to induce a state of metabolic insufficiency, where key catabolic intermediates are unavailable to enter a variety of metabolic recycling pathways ([@bib104]; [@bib126]). For example, in some cell types, the majority of nascent glycosphingolipids are synthesized from endolysosome-derived sphingoid bases derived from ceramide catabolism ([@bib117]; [@bib56]). Multiple endolysosomal exoglycosidases, including glucocerebrosidase, which is deficient in Gaucher disease, are involved in this process ([@bib57]). The lack of reutilized sphingolipids/fatty acids that normally result from endolysosomal degradation would place such cells under significant metabolic stress. This may also apply to NPC disease, which is a particularly complex and enigmatic storage disease caused by mutations in either the NPC1 or NPC2 genes, with resulting storage of several lipids species including cholesterol and various sphingolipids ([@bib68]). The NPC1 protein is an integral membrane protein of late endosomes that may function to efflux sphingosine (protonated at acidic pH) out of endolysosomes and into the sphingolipid salvage pathway or undergo phosphorylation to sphingosine-1-phosphate (S1P), raising the possibility that S1P deficiency contributes to NPC1 disease pathogenesis ([@bib69]; [@bib68]).

Therapeutic implications
========================

Over the past two decades there has been a remarkable expansion in the number of therapeutic strategies for LSDs that target different cellular organelles ([Table 2](#tbl2){ref-type="table"}). The first treatment that led to a licensed commercial product was enzyme replacement therapy (ERT) for type 1 Gaucher disease. The discoveries leading to that seminal therapeutic advance were recently reviewed by Roscoe Brady, who pioneered this approach ([@bib11]). This therapy "replaces" the defective enzyme in the lysosome by delivering a fully functional wild-type enzyme that is endocytosed into macrophages via the macrophage mannose receptor. Wild-type glucocerebrosidase was initially purified from human placenta (now recombinant products are used) and typically given to patients every two weeks by intravenous infusion ([@bib17]). This strategy leads to a remarkable degree of therapeutic benefit and has transformed the lives of patients with this debilitating peripheral storage disease ([@bib17]). This success catalyzed the development of ERT for Fabry disease ([@bib101]; [@bib1]), Pompe disease ([@bib1]), and several of the mucopolysaccharide storage disorders ([@bib52]). However, the clinical limitations of ERT are two-fold. First, product delivery is invasive and time-consuming to deliver, and second, lysosomal enzymes do not cross the blood--brain barrier to any significant extent, so cannot effectively treat CNS disease, which is characteristic of most LSDs. To circumvent this problem, bone marrow (BM) transplantation from healthy donors has been evaluated in some of these diseases. Microglia are of BM origin and over time a few donor-derived monocytes enter the CNS and serve as local sites of wild-type enzyme production, which can be taken up via secretion-recapture by neighboring host cells. On the whole, BM transplantation is only effective if it is performed in early infancy, does not show efficacy in all LSDs, and is not curative ([@bib134]). Further complications include the need for human leukocyte antigen (HLA) matched donors, the high rate of mortality associated with recipients, and the lack of standardization amongst different BMT regimens in different clinical centers.

###### 

Status of approved treatments and experimental therapies for LSDs with selected bibliography

  Therapy                                                  Target organelle   In vitro POC   In vivo POC   Clinical trials   Regulatory approval   References
  -------------------------------------------------------- ------------------ -------------- ------------- ----------------- --------------------- ------------------------------
  Enzyme replacement (ERT)                                 Lysosome           \+             \+            \+                \+                    [@bib10]; [@bib77]
  Bone marrow transplantation (BMT)                        Lysosome           \+             \+            \+                N/A                   [@bib61]; [@bib9]
  Substrate reduction therapy (SRT)                        Golgi              \+             \+            \+                \+                    [@bib86]; [@bib87]; [@bib22]
  Enzyme enhancement therapy (EET)                         ER/lysosome        \+             −             In progress       −                     [@bib79]; [@bib34]
  Gene therapy (GT)                                        Nucleus            \+             \+            In progress       −                     [@bib46]; [@bib119]
  Stop codon read-through                                  Nucleus            \+             −             −                 −                     [@bib14]
  Calcium modulation therapy (CMT)                         ER                 \+             \+            −                 −                     [@bib69]
  Enhanced exocytosis therapy (ExT)                        Exosome            \+             −             −                 −                     [@bib110]; [@bib71]
  Chaperone therapy by HSp70 (CT)                          Lysosome           \+             −             −                 −                     [@bib55]
  Proteostasis regulation therapy (PRT)                    ER                 \+             −             −                 −                     [@bib3]; [@bib74]
  Cholesterol removal using cyclodextrin in NPC1 disease   Lysosome           \+             \+            −                 −                     [@bib25]; [@bib128]; [@bib2]

POC, proof of concept.

Another therapy to be developed and subsequently approved for LSDs was substrate reduction therapy using the oral small molecule imino sugar drug, miglustat ([@bib63]). This has been approved for type 1 Gaucher disease (worldwide) for over a decade, and in 2009 for treating neurological manifestations in Niemann-Pick type C disease (now approved in most countries/regions, except the USA; [@bib83]). Miglustat targets the Golgi enzyme, glucosylceramide synthase ([@bib89]), and by partially inhibiting glycosphingolipid biosynthesis it reduces the catabolic burden of these molecules on lysosomes that cannot digest them. It has the potential to be used in diseases with glycosphingolipid storage, as miglustat inhibits the first committed step in the biosynthesis of this family of lipids. Also, miglustat crosses the blood--brain barrier, hence its disease-modifying benefit in Niemann-Pick type C disease ([@bib83]). Like all drugs, this compound has side effects, the primary one being inhibition of disaccharidases, which can lead to gastrointestinal symptoms, particularly in the first 1--2 months of therapy. More recently, eliglustat tartrate (Genz-112638) has entered clinical trials in type 1 Gaucher disease as an oral substrate reduction therapy. As this drug has a different chemistry to miglustat, it also has a different side-effect profile ([@bib22]).

There are currently several alternative therapeutic strategies that have shown utility in tissue culture models and/or in animal models of these diseases and are summarized in [Table 2](#tbl2){ref-type="table"}. Many of these approaches target non-lysosomal organelles. No doubt as more is known about pathogenic cascades and their impact on cellular organelles, additional creative approaches to treatment will emerge and undergo pre-clinical testing. Due to the severity and complexity of these disorders it is likely that ultimately a combination therapy will be needed to target multiple steps/organelles in the pathogenic cascade.

Conclusion
==========

In conclusion, we have provided some selective examples illustrating the complexity of how lysosomal dysfunction impinges upon multiple aspects of cell biology, often in unanticipated ways (summarized in [Fig. 3](#fig3){ref-type="fig"}). Many questions remain unanswered at the present time, and some of these are highlighted in [Box 1](#box1){ref-type="boxed-text"}. However, the study of these rare diseases ([Table 1](#tbl1){ref-type="table"}) fills two voids in our knowledge, namely providing fundamental insights into lysosomal biology and in leading to novel approaches to generate next-generation therapeutic interventions for treating these truly fascinating yet devastating disorders ([Table 2](#tbl2){ref-type="table"}). It is clear that although storage is primarily initiated in the late endosomal--autophagic--lysosomal system, it induces a pathogenic cascade that impacts on multiple cellular systems and organelles, suggesting that conceptually we should view these diseases as cellular storage disorders and use this broader knowledge for the design of therapeutic interventions.

Box 1. Open Questions
---------------------

• How does storage affect other aspects of lysosomal function, independent of the primary storage metabolite?

• How does storage trigger innate immune activation?

• How does lysosomal storage affect cell signaling?

• How do storage lipids escape the lysosome and affect the function of other organelles?

• What is the hierarchy of the pathogenic cascade in these diseases, which steps should be targeted for optimal therapy?

• Do the genetic defects in the neuronal ceroid lipofuscinoses (NCL disorders) cause convergent symptoms by chance, or are the disparate genes functioning in common cell biological pathways?
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